Aclaris Therapeutics(ACRS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ACRS Aclaris Therapeutics

盘后交易 06-29 19:29:33 EDT

5.02

+0.02

+0.40%

盘后5.02

+0.000.00%

18:04 EDT

最高5.07	最低4.86	成交量184.08万
今开5.00	昨收5.00	日振幅4.10%
总市值7.03亿	流通市值4.84亿	总股本1.40亿
成交额920.80万	换手率1.91%	流通股本9,642万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":5.02,"timestamp":1782763200000,"preClose":5,"halted":0,"volume":1840847,"hourTrading":{"tag":"盘后","latestPrice":5.02,"preClose":5.02,"latestTime":"18:04 EDT","volume":27700,"amount":139053.94460000002,"timestamp":1782770663794,"change":0,"changeRate":0,"amplitude":0.006932},"delay":0,"changeRate":0.003999999999999915,"floatShares":96417099,"shares":140000000,"eps":-0.561022,"marketStatus":"盘后交易","change":0.02,"latestTime":"06-29 19:29:33 EDT","open":5,"high":5.065,"low":4.86,"amount":9207968.237716,"amplitude":0.041,"askPrice":5.47,"askSize":100,"bidPrice":4.57,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.561022,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782777600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":5,"preHourTrading":{"tag":"盘前","latestPrice":5,"preClose":5,"latestTime":"09:29 EDT","volume":159,"amount":795.200022,"timestamp":1782739799999,"change":0,"changeRate":0,"amplitude":0.02},"postHourTrading":{"tag":"盘后","latestPrice":5.02,"preClose":5.02,"latestTime":"18:04 EDT","volume":27700,"amount":139053.94460000002,"timestamp":1782770663794,"change":0,"changeRate":0,"amplitude":0.006932},"volumeRatio":0.600201,"impliedVol":1.0512,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"1139349854","title":"Aclaris Therapeutics公布2026年第一季度财务业绩并更新公司及临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1139349854","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139349854?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:00","pubTimestamp":1778151628,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics已正式披露其2026年第一季度的财务报告，同时向市场通报了公司运营与临床研发项目的最新动态。此次发布涵盖关键财务数据及业务发展要闻，为投资者提供了全面评估公司近期表现与未来战略方向的依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114320072","title":"Aclaris Therapeutics公司ATI-052药物一期B阶段试验持续招募中 关键数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1114320072","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114320072?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:32","pubTimestamp":1777372325,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics公司宣布，其研发药物ATI-052的一期B阶段临床试验目前正在积极推进患者招募工作。该试验旨在评估该候选药物的安全性与有效性，公司计划于2026年下半年公布核心研究结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145747695","title":"Aclaris Therapeutics公布ATI-052一期临床试验积极顶线结果 并确立ATI-2138治疗扁平苔藓为首要适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1145747695","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145747695?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:31","pubTimestamp":1777372310,"startTime":"0","endTime":"0","summary":"生物制药公司Aclaris Therapeutics宣布，其潜在首创双特异性抗体ATI-052在1a期健康志愿者临床试验中获得完整的积极顶线人体数据。该候选药物靶向TSLP/IL-4Rα通路，展现良好安全性与药代动力学特征。同时，该公司明确将口服ITK/JAK3抑制剂ATI-2138的首个适应症聚焦于扁平苔藓治疗。两项进展标志着Aclaris在免疫炎症领域双管齐下的研发布局：ATI-052通过双靶点协同作用阻断炎症级联反应，而ATI-2138则借助口服给药优势精准调控免疫细胞功能。公司计划基于现有数据推进后续临床开发策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164258811","title":"Aclaris Therapeutics试验显示：抗药抗体对PK/PD参数无显著影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1164258811","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164258811?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:31","pubTimestamp":1777372303,"startTime":"0","endTime":"0","summary":"在Aclaris Therapeutics最新公布的临床试验数据中，研究人员发现抗药抗体的产生并未对药物代谢动力学和药效学参数产生实质性影响。这一发现为Aclaris Therapeutics相关药物的持续开发提供了重要支持，消除了关于抗体干扰药物疗效的潜在担忧。值得注意的是，试验过程中对PK参数和PD指标的监测数据显示，无论患者是否产生抗药抗体，其药物暴露水平和药理反应均保持稳定。这一结论为后续临床试验的设计和药物申报奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177102962","title":"Aclaris Therapeutics将于2026年4月28日公布核心生物制剂与口服抑制剂项目临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1177102962","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177102962?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:46","pubTimestamp":1777322771,"startTime":"0","endTime":"0","summary":"生物制药公司Aclaris Therapeutics宣布，计划于2026年4月28日对外披露其关键生物制剂与口服抑制剂研发项目的临床数据更新。此次更新将涵盖公司在研管线中具有战略意义的核心疗法，为投资者与行业观察者提供最新研发动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129994478","title":"Aclaris Therapeutics公布ATI-2138二期a阶段试验结果，将于2026年美国皮肤病学会年会展示海报","url":"https://stock-news.laohu8.com/highlight/detail?id=1129994478","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129994478?lang=zh_cn&edition=full","pubTime":"2026-03-20 23:03","pubTimestamp":1774019008,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics宣布，其候选药物ATI-2138的二期a阶段临床试验结果将以海报形式，在2026年美国皮肤病学会（AAD）年度会议上进行展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125195733","title":"Aclaris Therapeutics完成特应性皮炎药物Bosakitug二期临床试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1125195733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125195733?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:56","pubTimestamp":1773831379,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics宣布，其用于治疗特应性皮炎的候选药物Bosakitug二期临床试验已完成患者入组工作。本次二期试验旨在评估Bosakitug在中度至重度特应性皮炎患者中的安全性、耐受性及初步疗效。Bosakitug作为一种局部外用药物，若证实有效，可能提供差异化的治疗选择。Aclaris Therapeutics是一家专注于免疫炎症性疾病及皮肤病治疗的临床阶段生物制药公司。Bosakitug的进展是其皮肤病管线推进的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119979974","title":"Aclaris Therapeutics启动二期B阶段计划，涵盖哮喘与特应性皮炎，预计2026年下半年展开","url":"https://stock-news.laohu8.com/highlight/detail?id=1119979974","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119979974?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:09","pubTimestamp":1771934969,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics宣布，其针对哮喘及特应性皮炎的二期B阶段临床研究计划预计将于2026年下半年正式启动。这一进展标志着公司在炎症性皮肤病与呼吸疾病治疗领域的研发迈出关键一步。\n该计划旨在评估候选药物在更广泛患者群体中的疗效与安全性，为后续临床试验奠定基础。随着研究推进，公司有望进一步明确其创新疗法的市场潜力与发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121318232","title":"Aclaris Therapeutics启动针对哮喘患者的1B期概念验证试验，评估其新型双特异性抗TSLP/IL-4Rα抗体ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=1121318232","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121318232?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:03","pubTimestamp":1771934637,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics宣布，已正式启动一项针对哮喘患者的1B期概念验证临床试验。该试验旨在评估其研发的新型双特异性抗体ATI-052的疗效与安全性，该抗体靶向作用于TSLP和IL-4Rα。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192452610","title":"Aclaris Therapeutics新型Itk/Jak3抑制剂ATI-2138在验证性斑秃小鼠模型中展现快速且持久的毛发再生效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1192452610","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192452610?lang=zh_cn&edition=full","pubTime":"2026-01-27 19:56","pubTimestamp":1769514971,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics公司研发的新型Itk/Jak3抑制剂ATI-2138，在经科学验证的斑秃小鼠模型中，成功实现了快速且持久的毛发再生。这一重要发现为斑秃治疗领域带来了新的希望，展示了该候选药物在调节免疫系统以促进毛发生长方面的显著潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161570748","title":"Aclaris Therapeutics启动新型双特异性抗体ATI-052治疗特应性皮炎的1B期概念验证试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1161570748","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161570748?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:56","pubTimestamp":1768218991,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics（股票代码：ACRS）已正式启动其创新双特异性抗体ATI-052针对特应性皮炎（AD）的1B期概念验证临床试验。该试验旨在评估ATI-052在患者中的初步疗效与安全性，标志着公司在该治疗领域的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128928153","title":"Aclaris Therapeutics公布ATI-052抗TSLP/IL-4Rα双特异性抗体1a期试验中期积极结果，支持加速临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1128928153","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128928153?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:59","pubTimestamp":1767700758,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics今日宣布，其创新药物ATI-052——一款靶向TSLP/IL-4Rα的双特异性抗体，在1a期临床试验中取得了积极的中期结果。这一关键进展为后续的加速临床开发计划提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517461224","title":"Aclaris Therapeutics(ACRS.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价15.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461224","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517461224?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics(ACRS.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价15.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ACRS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163304129","title":"Aclaris Therapeutics 2024年第四季度GAAP每股收益$(1.01)低于预期$(0.24)，销售额$9.21M高于预期$2.11M","url":"https://stock-news.laohu8.com/highlight/detail?id=1163304129","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163304129?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:20","pubTimestamp":1740658810,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics报告称，季度每股亏损$，低于分析师一致预期的$，差距高达320.83%。公司报告季度销售额为$9.21百万，高于分析师一致预期的$2.11百万，超出预期336.89%。相比去年同期的$17.57百万销售额下降了47.58%。以上内容来自Benzinga Earnings专栏，原文如下：$Aclaris Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 320.83 percent.  The company reported quarterly sales of $9.21 million which beat the analyst consensus estimate of $2.11 million by 336.89 percent.  This is a 47.58 percent decrease over sales of $17.57 million the same","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aclaris Therapeutics 2024年第四季度GAAP每股收益$(1.01)低于预期$(0.24)，销售额$9.21M高于预期$2.11M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512848955","title":"Aclaris Therapeutics, Inc.盘中异动 早盘急速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512848955","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512848955?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:41","pubTimestamp":1739979660,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时41分，Aclaris Therapeutics, Inc.股票出现波动，股价快速拉升5.00%。Aclaris Therapeutics, Inc.股票所在的生命科学行业中，整体涨幅为0.79%。其相关个股中，Prophase Labs, Inc.、Grail, Inc.、Prenetics Global Limited C/Wts 18/05/2027 涨幅较大，Prophase Labs, Inc.、Mainz Biomed N.V.、Ispecimen Inc.较为活跃，换手率分别为52.27%、4.78%、2.59%，振幅较大的相关个股有Prenetics Global Limited C/Wts 18/05/2027 、Prophase Labs, Inc.、Genedx Holdings Corp C/Wts 22/07/2026 ，振幅分别为34.78%、18.22%、12.36%。Aclaris Therapeutics, Inc.公司简介：Aclaris Therapeutics Inc 是一家在美国运营的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234100a24c0945&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234100a24c0945&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511006615","title":"Aclaris Therapeutics, Inc.盘中异动 下午盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511006615","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511006615?lang=zh_cn&edition=full","pubTime":"2025-02-15 02:39","pubTimestamp":1739558372,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时39分，Aclaris Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。截至发稿，该股报2.31美元/股，成交量19.5529万股，换手率0.18%，振幅5.91%。Aclaris Therapeutics, Inc.股票所在的生命科学行业中，整体涨幅为0.04%。其相关个股中，Neuronetics, Inc.、燃石医学、Personalis, Inc.涨幅较大，Prophase Labs, Inc.、Mainz Biomed N.V.、Grail, Inc.较为活跃，换手率分别为38.46%、12.52%、5.82%，振幅较大的相关个股有Bioaffinity Technologies Inc C/Wts 07/09/2027 、Prophase Labs, Inc.、Personalis, Inc.，振幅分别为46.14%、36.74%、20.04%。Aclaris Therapeutics, Inc.公司简介：Aclaris Therapeutics Inc 是一家在美国运营的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215023932a24635f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215023932a24635f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ACRS","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510623338","title":"Aclaris Therapeutics, Inc.盘中异动 股价大跌5.02%报2.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510623338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510623338?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:45","pubTimestamp":1739285107,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时45分，Aclaris Therapeutics, Inc.股票出现波动，股价急速下跌5.02%。截至发稿，该股报2.27美元/股，成交量2.1301万股，换手率0.02%，振幅3.35%。Aclaris Therapeutics, Inc.股票所在的生命科学行业中，整体跌幅为0.35%。Aclaris Therapeutics, Inc.公司简介：Aclaris Therapeutics Inc 是一家在美国运营的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211224507961f4a63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211224507961f4a63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ACRS","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509207333","title":"Aclaris Therapeutics, Inc.盘中异动 下午盘股价大跌5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509207333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509207333?lang=zh_cn&edition=full","pubTime":"2025-02-07 02:02","pubTimestamp":1738864933,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日02时02分，Aclaris Therapeutics, Inc.股票出现波动，股价大幅下跌5.64%。Aclaris Therapeutics, Inc.股票所在的生命科学行业中，整体跌幅为0.94%。其相关个股中，Neuronetics, Inc.、Endra Life Sciences Inc.、Genedx Holdings Corp C/Wts 22/07/2026 涨幅较大，Ispecimen Inc.、Mainz Biomed N.V.、Inotiv, Inc.较为活跃，换手率分别为14.95%、12.62%、3.97%，振幅较大的相关个股有Bioaffinity Technologies Inc C/Wts 07/09/2027 、Mainz Biomed N.V.、Prophase Labs, Inc.，振幅分别为25.50%、14.00%、13.63%。Aclaris Therapeutics, Inc.公司简介：Aclaris Therapeutics Inc 是一家在美国运营的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207020214abc4fedb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207020214abc4fedb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509646029","title":"Aclaris Therapeutics, Inc.盘中异动 下午盘股价大涨5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509646029","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509646029?lang=zh_cn&edition=full","pubTime":"2025-02-05 02:36","pubTimestamp":1738694213,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日02时36分，Aclaris Therapeutics, Inc.股票出现波动，股价大幅拉升5.21%。Aclaris Therapeutics, Inc.股票所在的生命科学行业中，整体跌幅为0.78%。其相关个股中，Exagen Inc.、Bioaffinity Technologies Inc C/Wts 07/09/2027 、Neuronetics, Inc.涨幅较大，Mainz Biomed N.V.、Ispecimen Inc.、Exagen Inc.较为活跃，换手率分别为14.40%、10.08%、5.13%，振幅较大的相关个股有Bioaffinity Technologies Inc C/Wts 07/09/2027 、Exagen Inc.、安奈特保险，振幅分别为28.48%、26.31%、22.56%。Aclaris Therapeutics, Inc.公司简介：Aclaris Therapeutics Inc 是一家在美国运营的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205023654987a702c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205023654987a702c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507965738","title":"Aclaris Therapeutics, Inc.盘中异动 股价大涨6.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507965738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507965738?lang=zh_cn&edition=full","pubTime":"2025-01-31 22:30","pubTimestamp":1738333847,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日22时30分，Aclaris Therapeutics, Inc.股票出现波动，股价快速上涨6.28%。截至发稿，该股报2.54美元/股，成交量5.433万股，换手率0.05%，振幅0.42%。Aclaris Therapeutics, Inc.股票所在的生命科学行业中，整体涨幅为0.00%。其相关个股中，Mainz Biomed N.V.、Aclaris Therapeutics, Inc.、Oncocyte Corporation涨幅较大，Mainz Biomed N.V.、Ispecimen Inc.、T2 Biosystems, Inc.较为活跃，换手率分别为0.53%、0.21%、0.16%，振幅较大的相关个股有Personalis, Inc.、Grail, Inc.、赛默飞世尔，振幅分别为1.87%、1.43%、1.10%。Aclaris Therapeutics, Inc.公司简介：Aclaris Therapeutics Inc 是一家在美国运营的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312230479614ea84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312230479614ea84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.1111},{"period":"1month","weight":0.0917},{"period":"3month","weight":0.4205},{"period":"6month","weight":0.6502},{"period":"1year","weight":2.2051},{"period":"ytd","weight":0.6611}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aclaris Therapeutics, Inc.于2012年7月在美国特拉华州成立。该公司是一家临床阶段的生物制药公司，专注于开发免疫炎症疾病的新型候选药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.021975},{"month":4,"riseRate":0.454545,"avgChangeRate":0.005147},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.034939},{"month":6,"riseRate":0.636364,"avgChangeRate":0.004485},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aclaris Therapeutics(ACRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aclaris Therapeutics(ACRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}